By performing a co-mutation plot of mutations identified with the highest incidences in these patients, we showed that TP53 mutations (52.38%) appear most frequently in ctDNA taken from patients with all types of lung cancers, followed by EGFR mutations (~40%) that exhibit strong preference to patients with adenocarcinoma (Fig. 6a and c). This evidence concerns the gene TP53 and adenocarcinoma.